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OBJECTIVE
To determine whether the use of continuous glucose monitoring (CGM) without
confirmatory blood glucose monitoring (BGM) measurements is as safe and ef-
fective as using CGM adjunctive to BGM in adults with well-controlled type 1
diabetes (T1D).
RESEARCH DESIGN AND METHODS
A randomized noninferiority clinical trial was conducted at 14 sites in the T1D
Exchange Clinic Network. Participants were ‡18 years of age (mean 44 6
14 years), had T1D for ‡1 year (mean duration 24 6 12 years), used an insulin
pump, and had an HbA1c £9.0% (£75 mmol/mL) (mean 7.0 6 0.7% [53 6
7.7 mmol/mol]); prestudy, 47% were CGM users. Participants were randomly
assigned 2:1 to the CGM-only (n = 149) or CGM+BGM (n = 77) group. The primary
outcome was time in range (70–180 mg/dL) over the 26-week trial, with a prespe-
cified noninferiority limit of 7.5%.
RESULTS
CGMuseaveraged6.76 0.5 and6.86 0.4 days/week in theCGM-only andCGM+BGM
groups, respectively, over the 26-week trial. BGM tests per day (including the two
required daily for CGM calibration) averaged 2.8 6 0.9 and 5.4 6 1.4 in the two
groups, respectively (P < 0.001). Mean time in 70–180mg/dL was 636 13% at both
baseline and 26 weeks in the CGM-only group and 656 13% and 656 11% in the
CGM+BGM group (adjusted difference 0%; one-sided 95% CI 22%). No severe
hypoglycemic events occurred in the CGM-only group, and one occurred in the
CGM+BGM group.
CONCLUSIONS
Use of CGM without regular use of confirmatory BGM is as safe and effective as
using CGM with BGM in adults with well-controlled T1D at low risk for severe
hypoglycemia.
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In the past decade, continuous glucose
monitoring (CGM) has evolved as an es-
sential part of diabetes management for
many people with type 1 diabetes (T1D)
(1–3). This technology offers advantages
to traditional self-monitoring of blood
glucose by providing real-time informa-
tion on high- and low-glucose patterns,
directions and rate of glucose changes,
and hypo/hyperglycemia alerts. Several
multicenter randomized controlled tri-
als have demonstrated the benefits of
CGM in reducing HbA1c and hypoglyce-
mia, particularly in adults with T1D
(2,4–11).
Before December 2016, the CGM sys-
tems commercially available in the U.S.
were approved by the U.S. Food and
Drug Administration (FDA) for use only
as adjunctive devices to information ob-
tained from standard home blood
glucose monitoring (BGM). Therefore,
according to the labeling of these
CGM systems, a BGM measurement
was required to confirm the CGM sensor
glucose concentration before making an
insulin dosing decision. This regulatory
decision presumably was made because
the accuracy of the CGM systems was
considered to be inadequate for dosing
insulin without BGM confirmation. How-
ever, with each new generation of sen-
sors, accuracy has improved (12–17),
suggesting that CGM may now be suffi-
ciently accurate to be safely imple-
mented as a stand-alone tool for glucose
monitoring and therapeutic decisions.
In December 2016, the FDA expanded
the indications for the Dexcom G5 sen-
sor (Dexcom, San Diego, CA) to allow
for replacement of fingerstick blood
glucose testing for diabetes treatment
decisions.
Even when the FDA labeling limited
CGM use to an adjunct-only tool, many
CGM users were making insulin dosing
decisions by CGM alone. Among adult
participants in the T1D Exchange Clinic
registry, only 26% of 999 surveyed
CGM users indicated that they always
confirmed the CGM glucose concentra-
tion with a BGM measurement before
administering an insulin bolus, and
41% indicated that they dosed insulin
based on CGM alone more than one-
half of the time (R.W.B., unpublished
data). In another survey of 222 CGM
users, 50% of respondents indicated
that during the night, they would
treat a CGM low-glucose alert without
a confirmatory fingerstick glucose, and
34% would dose insulin for hyperglyce-
mia without a confirmatory BGM mea-
surement (18).
To date, no clinical trials have con-
firmed the safety and effectiveness of
CGM used without BGM to make thera-
peutic decisions in people with T1D. We
conducted a multicenter randomized
noninferiority clinical trial to determine
whether the routine use of CGM with-
out BGM confirmation is as safe and
effective as CGM used as an adjunct to
BGM in adults with T1D.
RESEARCH DESIGN AND METHODS
The trial was conducted at 14 endocri-
nology practices in the U.S. of which
4 were community-based and 10 were
academic centers. The protocol and
Health Insurance Portability and Ac-
countability Act–compliant informed
consent forms were approved by insti-
tutional review boards. Written in-
formed consent was obtained from
each participant. The study is listed
on ClinicalTrials.gov under identifier
NCT02258373. An investigational device
exemption was obtained from the FDA
to conduct the trial. The full protocol is
available at http://t1dexchange.org/
pages/resources/clinic-network/studies
and is summarized below.
Study Participants
Major eligibility criteria were age $18
years, T1D for $1 year being treated
with an insulin pump for at least
3 months (and not currently using a low-
glucose-suspend function), and point of
care HbA1c#9.0% (#75mmol/mol). Exclu-
sion criteria included the occurrence of a
severe hypoglycemic event resulting in sei-
zure or loss of consciousness in the past
3 years or an event without seizure or loss
of consciousness requiring the assistance of
another individual in the past 12 months,
significant hypoglycemia unawareness
based on the Clarke Hypoglycemia Un-
awareness Survey (19),.10.0% of baseline
CGM glucose concentrations ,60 mg/dL,
more than one episode of diabetic ke-
toacidosis (DKA) in the past year, history
of seizures other than those due to
hypoglycemia, current use of a thresh-
old-suspend pump feature, myocardial
infarction or stroke in the past 6months,
estimated glomerular filtration rate
,30 mL/min/1.73 m2, abnormal thyroid
function, use of a systemic b-blocker,
regular use of oral corticosteroids, initi-
ation of a noninsulin drug for glucose
control during the past 3 months, preg-
nancy, inpatient psychiatric treatment
in the past 6 months, and presence
of a contraindicated medical condition
or medication, including ongoing use of
acetaminophen. (Supplementary Table
1 provides a complete list of the inclu-
sion and exclusion criteria.)
Synopsis of Study Design
A run-in phase of 2–10 weeks preceded
the 6-month randomized trial. After suc-
cessful completion of the run-in phase
and after verification of eligibility from
data entered on the study website,
each participant was randomly assigned
from a computer-generated sequence
to the CGM-only or CGM+BGM group
in a 2:1 ratio on the basis of a permuted
block design with stratification by clin-
ical site. Both groups used a Dexcom
G4 Platinum CGM System with an en-
hanced algorithm (Software 505) (re-
ferred to as the study CGM), which
measures glucose concentrations from
interstitial fluid in the range of 40–
400 mg/dL every 5 min for up to 7 days.
The study BGM was the CONTOUR
NEXT (Ascensia Diabetes Care US, Par-
sippany, NJ). The Abbott Precision Xtra
(Abbott Diabetes Care, Alameda, CA)
was used to measure blood ketone lev-
els (b-hydroxybutyrate).
Run-in Phase
Informed consent was signed by 295 in-
dividuals, 19 of whom did not pass the
screening assessment. The run-in phase,
which was initiated by 276 participants,
lasted for 2–10 weeks, depending on
whether the participant was a CGM
user at the time of study entry. There
were two parts of the run-in phase of
which participants completed various
portions, depending on whether they
were using CGM at study entry: 1) Dex-
com CGM system configured to record
glucose concentrations not visible to the
participant (referred to as a blinded
CGM) for 14 days to collect baseline
data and 2) standard CGM for 2–8weeks
for CGM training. In both phases, the
participant’s willingness and ability to
use the study CGM and BGM were as-
sessed. Participants who used a Dexcom
CGM for at least 21 of the 28 days before
study enrollment skipped the blinded
CGM phase and were required to have
only 2 weeks of unblinded study CGM
care.diabetesjournals.org Aleppo and Associates 539
use. Participants who used a Medtronic
CGM for at least 21 of the 28 days before
enrollment skipped the blinded CGM
phase andwere required to have at least
4 weeks of unblinded study CGM use.
All other participants completed the
14-day blinded phase and 8 weeks of
unblinded CGM use. Successful comple-
tion of the blinded phase required study
CGM wear on a minimum of 11 of
14 days and an average of three blood
glucose measurements per day by the
study BGM. Successful completion of
the unblinded CGM phase required
CGM use on $21 days during the past
28 days and an average of four or more
BGM measurements on at least 90% of
days; for participants whose run-in
phase was shortened, the number of
days of CGM use were reduced accord-
ingly. Of 276 participants who entered
the run-in phase, 50 did not enter the
randomized trial for the following rea-
sons: 24 did not meet the BGM crite-
rion, 6 had .10% of CGM readings of
,60 mg/dL, and 20 were withdrawn for
avariety of other reasons (Supplementary
Figs. 1 and 2).
Randomized Trial
After randomization, participants in
both groups were instructed to calibrate
the study CGM per Dexcom specifica-
tions and to use it daily. Both groups
also were instructed to perform a BGM
measurement when the fasting CGM
glucose concentration was .300 mg/dL
or when the CGM glucose concentra-
tion during the day was .300 mg/dL
for 1 h. In both instances, if the BGM
measurement confirmed that the glu-
cose level was .300 mg/dL, the partic-
ipant was instructed to perform a blood
ketone measurement with the study
ketone meter.
The CGM+BGM group was in-
structed to perform a BGM measure-
ment with the study meter for CGM
calibrations whenever an insulin bolus
was administered, when treating or at-
tempting to prevent hypoglycemia,
and before going to bed. The CGM-
only group was instructed to dose in-
sulin and make management decisions
on the basis of the CGM sensor glucose
concentration, except in the follow-
ing circumstances that required
BGM testing: 1) for 12 h after insertion
of a new sensor, 2) on a sick day (e.g.,
nausea, vomiting), 3) for 4 h after taking
acetaminophen, 4) for symptoms sugges-
tive of hypoglycemia but the CGM sensor
glucose concentration was not hypogly-
cemic or dropping rapidly, 5) for 20 min
after treating a low CGM sensor glucose
concentration if the CGM sensor glucose
level had not begun to rise, 6) before
administering an insulin bolus when
the CGM sensor glucose concentration
was.250mg/dL, and 7) for a fastingCGM
glucose.300mg/dL or CGMglucose con-
centration during the day.300mg/dL for
1 h. If a CGM calibration measurement
coincided with a meal, the participant
was instructed to base the meal bolus
on the CGM sensor value and then
perform a BGMmeasurement to calibrate
the CGM.
Follow-up visits for both groups oc-
curred at 3, 6, 13, 19, and 26 weeks,
with a 61-week window. Data were
uploaded from the study CGM and
BGM devices and the participant’s per-
sonal insulin pump by using the Tide-
pool platform (http://tidepool.org).
For insulin pumps that were unable to
be uploaded to the Tidepool platform,
the data were obtained by using Dia-
send (Chicago, IL) software. At each
visit, compliance with CGM and BGM
use was assessed, and additional train-
ing was given as needed. Glucose and
pump data were reviewed to deter-
mine whether changes were indicated
in diabetes management.
HbA1c was measured at baseline,
13 weeks, and 26weeks at the Northwest
Lipid Research Laboratories, University of
Washington, by using the Diabetes Con-
trol and Complications Trial standardized
analyzer (Tosoh Bioscience, South San
Francisco, CA). The following question-
naires were completed at baseline and
26weeks: the Diabetes Technology Ques-
tionnaire, which consists of 30 questions
about diabetes self-treatment practices
and the impact of living with diabetes
on the individual (20), and the Hypogly-
cemia Fear Survey, which consists of
23 questions about the effect of or worry
about hypoglycemia on the individual
with diabetes (21).
Study Outcomes
TheprimaryoutcomewasCGM-measured
time in the range of 70–180 mg/dL over
the entire 26-week trial. To be in-
cluded in the primary and secondary
analyses of CGMmetrics, the participant
had to have at least 200 h of CGM data
during the 26 weeks of the trial. Second-
ary outcomes included CGM measures
of mean glucose, glycemic variability (co-
efficient of variation), hypoglycemia (time
,70 mg/dL, 60 mg/dL, and 50 mg/dL;
area above curve 70 mg/dL; and percent-
age of days with $20 consecutive min
of glucose concentrations ,60 mg/dL),
hyperglycemia (time .180 mg/dL,
250 mg/dL, 300 mg/dL; area under the
curve 180 mg/dL; and percentage of
days with $20 consecutive min of
glucose concentrations .300 mg/dL),
change in HbA1c, and proportion of par-
ticipants with both no worsening of
HbA1c by .0.3% (3.3 mmol/mol) and
no severe hypoglycemic event. Safety
outcomes were severe hypoglycemia
(defined as an event that required assis-
tance from another person to administer
carbohydrate, glucagon, or other resus-
citative actions); DKA; hyperglycemia
not meeting the definition of DKA for
which emergency evaluation or treat-
ment was obtained from a health care
provider or blood ketone levels $0.6
or $1.0 mmol/L; and other occurrences
meeting the regulatory definition of a se-
rious adverse event.
Statistical Methods
Sample size was determined for a nonin-
feriority limit of 7.5% for the difference
between treatment groups in the time
in the range of 70–180 mg/dL over the
course of 26 weeks. For 90% power, a
one-sided a of 0.05, and assuming an
SD of 14% with correlation of 0.48 be-
tween the baseline and outcome time
in range (based on data from the JDRF
CGM randomized trial [8]), the re-
quired sample size was estimated to
be 122. However, to better assess
CGM-only safety, the sample size was
selected to be 225 participants ran-
domly assigned 2:1 to the CGM only
group or CGM+BGM group.
Analyses followed the intention-to-
treat principle. The primary analysis
was a treatment group comparison of
time in range (70–180 mg/dL) during
the 26-week trial by using an ANCOVA
model adjusted for baseline time in
range and site as a random effect. Con-
founding was assessed by repeating
the analysis with the inclusion of po-
tential confounding variablesas covariates.
Prespecified exploratory analyses were
conducted to assess for interaction
between the treatment effect on the
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time in range (70–180 mg/dL) during
the 26-week trial and baseline factors
by including interaction terms in the
ANCOVA models. For the remaining
CGM outcomes, treatment group com-
parisons were made by using ANCOVA
models based on van der Waerden
score rankings if the metric was skewed
and adjusted for the corresponding
baseline value and clinical site as a ran-
dom effect.
Change in HbA1c from baseline was
compared between groups by using an
ANCOVA model adjusted for baseline
HbA1c and site as a random effect.
The proportions of participants with
both no worsening of HbA1c by .0.3%
(3.3 mmol/mol) and no severe hypogly-
cemic event were compared between
treatment groups by using a logistic re-
gression model adjusted for baseline
HbA1c and site as a random effect. The
percentages of subjects with at least
one blood ketone level $0.6 mmol/L
(and $1.0 mmol/L) were compared be-
tween treatment groups by using a lo-
gistic regression model adjusted for site
as a random effect. The mean scores on
the Diabetes Technology Questionnaire
were compared between treatment
groups by using ANCOVA models ad-
justed for site as a random effect. For
the Hypoglycemia Fear Survey, the
overall total score, the total score
for the low–blood glucose questions
(1–10), and the total score for the wor-
rying questions (11–23) were each
compared between treatment groups
by using an ANCOVA model adjusted
for the baseline value and site as a ran-
dom effect.
Analyses were conducted with SAS
9.4 software (SAS Institute, Cary, NC).
All P values are two-sided.
RESULTS
Between 22 May 2015 and 11 March
2016, 226 participants were assigned
to either the CGM-only group (n = 149)
or the CGM+BGM group (n = 77). Mean
age was 44 6 14 years (35 [15%] $60
years old), mean diabetes duration
was 246 12 years, and mean baseline
HbA1cwas7.060.7%(5367.7mmol/mol);
107 (47%) were CGM users, and 119
(53%) were not using CGMwhen enrolled.
Participant characteristics according to
treatment group are listed in Table 1.
One participant in the CGM-only group
was determined after randomization to
have been ineligible (percentage of
time ,60 mg/dL during blinded base-
line CGM wear was .10%). Seven par-
ticipants in the CGM-only group and
two in the CGM+BGM group withdrew
from the trial. Thus, the trial was com-
pleted by 142 (95%) of the CGM-only
group participants and by 75 (97%)
of the CGM+BGM group participants
(Supplementary Figs. 2 and 3).
Among participants completing the tri-
al, all in both groups were using CGM in
month6. CGMuse averaged6.760.5 and
6.86 0.4 days/week in the CGM-only and
CGM+BGM groups, respectively, over
the 26-week trial (Table 2), with 91%
and 95% averaging $6 days/week. All
participants in the CGM+BGM group
and all but one in the CGM-only group
averaged $5 days/week over the en-
tire 26 weeks. Among participants
$60 years old who completed the
study, 95% in the CGM-only group
(n = 21) and 92% in the CGM+BGM
group (n = 13) averaged $6 days/week,
and among participants ,60 years
old, 90% (n = 121) and 95% (n = 62)
averaged $6 days/week. Among the
Table 1—Participant characteristics at enrollment (N = 226 randomized)
CGM-only
group (n = 149)
CGM+BGM
group (n = 77)
Age (years) 44 6 14 45 6 13
Range 19–78 25–69
Diabetes duration (years) 23 6 12 25 6 12
Range 2–64 4–58
BMI (kg/m2) 27.7 6 4.1 26.5 6 4.9
Female sex 71 (48) 41 (53)
Race/ethnicity
White non-Hispanic 139 (93) 68 (88)
Hispanic or Latino 4 (3) 5 (6)
Black/African American 4 (3) 1 (1)
Asian 2 (1) 2 (3)
Other/unknown 0 (0) 1 (1)
Annual household income ($)*
,50,000 18 (16) 7 (12)
.50,000–100,000 39 (35) 17 (30)
$100,000 54 (49) 33 (58)
Highest education*
Less than bachelor’s degree 35 (24) 12 (16)
Bachelor’s degree 75 (51) 35 (48)
Postbachelor’s degree 38 (26) 26 (36)
Insurance*
Private 132 (89) 66 (88)
Other 15 (10) 7 (9)
None 2 (1) 2 (3)
CGM use before study
Never used CGM 26 (17) 14 (18)
In past, but not current 54 (36) 25 (32)
Current Dexcom CGM user 49 (33) 28 (36)
Current Medtronic CGM user 20 (13) 10 (13)
Central laboratory HbA1c value†
,7.0% (53 mmol/mol) 59 (40) 39 (51)
7.0–8.0% (53–64 mmol/mol) 79 (53) 31 (40)
$8.0% (64 mmol/mol) 11 (7) 7 (9)
% (mmol/mol) 7.1 6 0.7 (54 6 7.7) 7.0 6 0.7 (53 6 7.7)
Self-reported BGM testing times/day 5.2 6 2.1 4.9 6 1.9
Clarke Hypoglycemia Unawareness
Survey total score
0 100 (67) 53 (69)
1 34 (23) 14 (18)
2 15 (10) 10 (13)
Data are mean 6 SD or n (%) unless otherwise indicated. *Missing data for CGM-only and
CGM+BGM groups: annual income for 38 and 20, education for 1 and 4, and insurance for
0 and 2, respectively; †The local laboratory HbA1c value was used for one participant in
the CGM+BGM group whose central laboratory value was unavailable.
care.diabetesjournals.org Aleppo and Associates 541
completers of the trial, BGM tests per
day from meter downloads (including
the two required daily BGM tests)
averaged 2.8 6 0.9 in the CGM-only
group and 5.4 6 1.4 in the CGM+BGM
group (P , 0.001).
Glycemic Control and Other
Outcomes
Mean time spent in the range of 70–
180mg/dLwas 636 13%at bothbaseline
and 26 weeks in the CGM-only group and
656 13% and 656 11%, respectively, in
the CGM+BGM group (adjusted differ-
ence 0%; one-sided 95% CI 22%). Other
CGMmetrics of glucose control for mean
glucose, hyperglycemia, hypoglycemia,
and glycemic variability also showed little
change from baseline to 26 weeks and no
significant differences between groups
(Table 3). Mean change in HbA1c was
0.0% (0.0 mmol/mol) in each group (P =
0.41) (Table 3). Results were similar in
subgroups based on age, duration, edu-
cation, CGMuse before study enrollment,
baseline HbA1c, and baseline time in
Table 2—CGM use over the 26-week study period in participants completing
the trial
CGM use (days/week) CGM-only group (n = 142) CGM+BGM group (n = 75)
Median (interquartile range) 7.0 (6.5–7.0) 7.0 (6.7–7.0)
Mean 6 SD 6.7 6 0.5 6.8 6 0.4
3 to ,4 1 (,1) 0
4 to ,5 0 0
5 to ,6 12 (8) 4 (5)
6 to ,7 55 (39) 34 (45)
7 74 (52) 37 (49)
,6 13 (9) 4 (5)
$6 129 (91) 71 (95)
Data are n (%) unless otherwise indicated.
Table 3—Study outcomes
CGM-only group CGM+BGM group
CGM results
Baseline
(n = 149)
26-week study
period (n = 148)*
Baseline
(n = 77)
26-week study
period (n = 76)* P value†
Hours of CGM data 640 (620–650) 4,007 (3,709–4,166) 641 (619–651) 4,021 (3,725–4,136)
Range 306–663 467–4,399 270–684 811–4,535
% Time in range (70–180 mg/dL) 63 6 13 63 6 13 65 6 13 65 6 11 0.81
Mean glucose (mg/dL) 162 6 22 162 6 23 158 6 22 158 6 20 .0.99
Coefficient of variation (%) 36 (33–41) 37 (34–41) 37 (33–40) 37 (34–40) 0.58
Hypoglycemia‡
% Time ,70 mg/dL 2.9 (1.5–4.5) 3.0 (1.6–5.1) 3.6 (1.9–4.8) 3.7 (1.9–4.9) 0.95
% Time ,60 mg/dL 1.1 (0.6–1.9) 1.3 (0.5–2.4) 1.4 (0.6–2.3) 1.6 (0.6–2.2) 0.57
% Time ,50 mg/dL 0.3 (0.1–0.6) 0.4 (0.2–0.8) 0.4 (0.2–0.7) 0.5 (0.2–0.8) 0.75
Area above curve 70 mg/dL 0.3 (0.2–0.5) 0.3 (0.1–0.6) 0.4 (0.2–0.6) 0.4 (0.2–0.5) 0.76
% Days with $20 consecutive min
glucose values ,60 mg/dL 25 (15–43) 28 (13–42) 33 (15–43) 32 (16–46) 0.68
Hyperglycemia‡
% Time .180 mg/dL 33 (25–43) 35 (25–41) 31 (22–40) 31 (24–38) 0.88
% Time .250 mg/dL 8 (4–15) 9 (5–13) 7 (3–11) 7 (4–11) 0.65
% Time .300 mg/dL 2 (1–5) 2 (1–4) 2 (1–4) 2 (1–3) 0.72
Area under curve 180 mg/dL 17 (10–25) 17 (10–23) 14 (8–22) 15 (9–21) 0.90
% Days with $20 consecutive min of
glucose values .300 mg/dL
25 (12–48) 27 (14–40) 20 (8–36) 20 (10–37) 0.72
HbA1c results
Baseline
(n = 149)
Week 26 visit
(n = 142)
Baseline
(n = 77)
Week 26
visit (n = 75) P value†
HbA1c
% 7.1 6 0.7 7.1 6 0.7 7.0 6 0.7 7.0 6 0.6
mmol/mol 54 6 7.7 54 6 7.7 53 6 7.7 53 6 6.6
Change in HbA1c from baseline 0.41
% 0.0 6 0.5 0.0 6 0.5
mmol/mol 0.0 6 5.5 0.0 6 5.5
No worsening of HbA1c by .0.3%
(3.3 mmol/mol) and no severe
hypoglycemic event 115 (81) 54 (72) 0.15
Data are median (interquartile range), mean6 SD, or n (%) unless otherwise indicated. *One participant in the CGM-only group and one in the CGM
+BGM group never came in for a follow-up visit and therefore had no CGM data; †two-sided P value for the CGM metrics and change in HbA1c
are from ANCOVA models adjusted for the corresponding baseline value and site as a random effect. Because of the skewed distributions for the
CGM coefficient of variation, as well as the CGM hypoglycemia and hyperglycemia metrics, these models were based on van der Waerden score
rankings. The P value for the HbA1c/severe hypoglycemia combined outcome is from a logistic regression model adjusted for baseline HbA1c and
site as a random effect. Results were similar for the % time in range when also adjusting for education; ‡1% time equals 14.4 min/day.
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range (Table 4). CGM and HbA1c results
also were similar between groups in the
subset $60 years old (Supplementary
Table 2).
Severe Hypoglycemia and Other
Adverse Events
No severe hypoglycemic events oc-
curred in the CGM-only group, and one
occurred in the CGM+BGM group. No
occurrences of DKA occurred in ei-
ther group. Other serious adverse
events, unrelated to the study inter-
vention, occurred in four (3%) partici-
pants in the CGM-only group and three
(4%) in the CGM+BGM group (Supple-
mentary Table 3). A blood ketone level
$0.6 mmol/L occurred at least once in
48 (32%) participants in the CGM-only
group and 26 (34%) in the CGM+BGM
group (P = 0.79); the ketone level was
$1.0 mmol/L at least once in 27 (18%)
and 15 (19%) participants, respectively
(P = 0.84).
Questionnaires
Mean scores on the Diabetes Technol-
ogy Questionnaire were 3.6 6 0.6 in
the CGM-only group and 3.8 6 0.6 in
the CGM+BGM group at baseline and
3.66 0.6 in each group at 26 weeks (P =
0.58). There also was no significant
difference between groups on the sec-
tion of the questionnaire inquiring
about change from prestudy (P =
0.28) (Supplementary Table 4). On the
Hypoglycemia Fear Survey, total scores
were 29 6 11 in the CGM-only group
and 28 6 9 in the CGM+BGM group at
baseline and 32 6 11 and 31 6
11 at 26 weeks, respectively (P = 0.88)
(Supplementary Table 5).
CONCLUSIONS
This multicenter randomized trial was
conducted to determine whether using
CGM alone to make insulin dosing deci-
sions is as safe and effective as using
CGM as an adjunct to BGM. For the pri-
mary outcome of CGM-measured time
in the glucose range of 70–180 mg/dL,
use of CGM alone was shown to be non-
inferior to using CGM and BGM to-
gether. For this metric and all other
efficacy outcomes for CGM-measured
hyperglycemia, hypoglycemia, and glu-
cose variability, results in the CGM-
only and CGM+BGM groups were
virtually identical as were the HbA1c
results. Scores obtained from the Dia-
betes Technology Questionnaire and
Hypoglycemia Fear Survey also were
similar in the two groups. From a safety
perspective, no DKA events or severe
hypoglycemic episodes occurred in
the CGM-only group. Comparable re-
sults were found in participants who
were experienced CGM users at study
entry, in those who were CGM naive,
in older versus younger participants,
and in those with higher and lower
education levels. In both treatment
groups, mean time in range was simi-
lar at baseline and during follow-up,
likely reflecting the excellent glycemic
control of most participants entering
the trial.
To our knowledge, this randomized
trial is the first to assess the effective-
ness and safety of insulin dosing by
using CGM alone in adults with T1D.
In addition to randomization and mul-
tiple center participation, the strengths
of this study include a high degree of
participant retention, CGM use, and
treatment group adherence. Notably,
there was good separation between
the treatment groups in the number
of BGM tests per day, particularly
when recognizing that two of the
BGM measurements per day were re-
quired for CGM calibration and that
according to the protocol, the calibra-
tions were performed at times such
Table 4—Percent time in range (70–180 mg/dL) by group according to baseline factors
CGM-only group (n = 148)* CGM+BGM group (n = 76)*
n Baseline
26-Week
study period n Baseline
26-Week
study period
P value for
interaction†
Age 0.08
,50 years 94 60 6 13 60 6 13 45 65 6 13 65 6 13
$50 years 54 68 6 12 67 6 12 31 64 6 11 65 6 9
Diabetes duration 0.74
,25 years 87 62 6 13 63 6 12 41 67 6 12 66 6 11
$25 years 61 63 6 14 63 6 14 35 62 6 13 63 6 12
Education‡ 0.71
Less than bachelor’s degree 34 59 6 14 59 6 13 12 65 6 9 63 6 11
Bachelor’s degree or higher 113 64 6 13 64 6 13 61 66 6 13 65 6 11
CGM use before study
Never used 25 64 6 12 65 6 10 14 65 6 10 63 6 13 0.26
In past, but not current 54 58 6 13 57 6 14 24 62 6 14 63 6 13
Current Dexcom user 49 67 6 12 67 6 12 28 69 6 12 68 6 10
Current Medtronic user 20 64 6 13 63 6 11 10 59 6 8 61 6 7
Baseline HbA1c 0.20
,7.5% (58 mmol/mol) 108 67 6 11 66 6 11 60 69 6 10 68 6 9
$7.5% (58 mmol/mol) 40 51 6 10 52 6 12 16 50 6 9 52 6 10
Baseline time in range (70–180 mg/dL) 0.39
,60% 61 50 6 8 53 6 11 24 51 6 7 54 6 9
$60% 87 72 6 8 69 6 10 52 72 6 8 69 6 9
Data aremean6 SD unless otherwise noted. *One participant in the CGM-only group and one in the CGM+BGMgroup never came in for a follow-up
visit and therefore had no CGMdata; †P values obtained by including an interaction term in each ANCOVAmodel adjusted for baseline value and site
as a random effect. Continuous variable used in the models for age, duration, HbA1c, and baseline time in range; ‡education missing for one
participant in the CGM-only group and three participants in the CGM+BGM group.
care.diabetesjournals.org Aleppo and Associates 543
that they would not influence insulin
bolusing.
The major limitation of the trial re-
lates to the generalizability of the re-
sults based on the participant inclusion
and exclusion criteria. The trial cohort
included adults with T1D who used an
insulin pump and were well controlled
(mean HbA1c 7.0% [53 mmol/mol]) and
likely to adhere to the study protocol
and excluded individuals with significant
hypoglycemia unawareness or a sub-
stantial amount of CGM-measured hy-
poglycemia. Although the trial only
included pump users to be able to doc-
ument when an insulin bolus was given,
it seems reasonable to apply the results
to individuals who use multiple daily in-
jections of insulin who otherwise fit the
profile of the study participants because
the impact of sensor inaccuracy in de-
termining the amount of a bolus should
be similar in pump users and injection
users (8,22). The results of this study
support the need for future studies to
assess the safety of CGM used without
routine BGM testing in youth and in less-
compliant adults than those included in
this study, such as individuals with
higher HbA1c levels, who perform BGM
testing fewer than four times a day, and
with hypoglycemia unawareness (23).
The application of this trial’s results to
clinical practice can benefit people with
T1D by reducing their burden of multi-
ple daily fingersticks when using CGM
and can enhance the cost-effectiveness
of CGM therapy by reducing the number
of daily BGM test strips. Furthermore,
the demonstration that insulin dosing
based on CGM alone is safe has applica-
bility to assessing risk involved with ar-
tificial pancreas systems that automate
insulin delivery based on CGM sensor
glucose measurements.
In conclusion, in adults with well-
controlled T1D meeting the eligibility
criteria for this trial, use of CGM with-
out regular use of confirmatory BGM is
as safe and effective as using CGM
with a confirmatory BGMmeasurement
for insulin dosing.
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Appendix
Participating REPLACE-BG Study Group
sites from the T1D Exchange Clinic Network
with the principal investigator (PI), co-
investigator (I), and coordinator (C) in order by
the number of participants randomized per
site as of 4 November 2016. Detroit, Michigan,
Henry Ford Health System (n = 27), Davida Kruger
(PI), Terra Cushman (C); Los Angeles, California,
University of Southern California Community Dia-
betes Initiatives (n = 19), Anne Peters (PI), Mark
Harmel (C); Seattle, Washington, University of
Washington Diabetes Care Center (n = 19), Irl
Hirsch (PI), Dori Khakpour (C); Minneapolis, Min-
nesota, Park Nicollet International Diabetes Cen-
ter Adult Endocrinology (n = 18), Richard
Bergenstal (PI), Beth Olson (C); Chicago, Illinois,
Northwestern University (n = 18), Grazia Aleppo
(PI), Elaine Massaro (C), Teresa Pollack (C); Bos-
ton, Massachusetts, Joslin Diabetes Center Adult
Diabetes (n = 16), Elena Toschi (PI), Astrid Atakov-
Castillo (C); Portland, Oregon, Harold Schnitzer
Diabetes Health Center at Oregon Health & Sci-
ence University (n = 15), Andrew Ahmann (PI),
Kristin Jahnke (C); Aurora, Colorado, University
of Colorado/Denver, Barbara Davis Center for
Childhood Diabetes (n = 15), Viral N. Shah (PI),
Terra Thompson (C); Philadelphia, Pennsylvania,
UniversityofPennsylvaniaPerelmanSchool ofMed-
icine Penn Rodebaugh Diabetes Center (n = 15),
Michael Rickels (PI), Amy Peleckis (I), Shannon
O’Brien (I), Cornelia Dalton-Bakes (C); Atlanta,
Georgia, Atlanta Diabetes Associates (n = 14),
Bruce Bode (PI), Siana Tyler (C); San Diego, Cali-
fornia, Scripps Whittier Diabetes Institute (n =
14), Athena Philis-Tsimikas (PI), Rosario Rosal (C);
Ann Arbor, Michigan, University of Michigan (n =
13), Rodica Pop-Busui (PI), Cynthia Plunkett (C);
Tampa, Florida, University of South Florida Diabe-
tes Center (n = 12), Henry Rodriguez (PI), Emily
Eyth (C); Des Moines, Iowa, Iowa Diabetes and
Endocrinology Research Center (n = 8), Anuj
Bhargava (PI), Lisa Borg (C).
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